Assure Holdings Adds New Surgeon Partner in Texas and Performs First Case
PARKER, Colo., March 07, 2018 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (TSXV:IOM) (OTCQB:ARHH), a provider of intraoperative neuromonitoring services, has added Dr. Jeffrey Ratusznik to its network in the state of Texas. He has also just performed his first case as an Assure partner.
Dr. Ratusznik is a fellowship trained spine surgeon specializing in the evaluation and treatment of the full spectrum of spinal disorders, ranging from cervical and lumbar disc degeneration to the treatment of adult and pediatric spinal deformity, fractures, and complex revision procedures. He currently practices medicine in Fort Worth, Texas.
Commenting on the partnership, Ratusznik said: “I was attracted to Assure due to their turnkey approach and ability to provide consistent, high-quality intraoperative monitoring services for my patients. Having just performed my first surgery on their platform, the transition was seamless and I was impressed by the experience of my now designated technician. These factors were a driving force behind my decision to align with Assure, and I look forward to our partnership as it enables me to focus solely on helping my patients.”
Just last November, Assure performed its first case in Texas—an important event validating the scalability of Assure’s model outside of Colorado.
“Part of our mission when founding this company was to streamline the neuromonitoring process to help make the surgeon’s practice more efficient,” said Preston Parsons, founder and chairman of Assure. “We welcome Dr. Ratusznik to Assure and look forward to monitoring many more of his cases, allowing his team to do what they do best. We believe Texas has many more doctors like him, and we look forward to continuing our growth in this great state.”
About Assure Holdings
Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. While Assure focuses primarily on supporting spinal and vascular surgeries, plans are in place to support other classes of medicine that rely on the standard of care that intraoperative neuromonitoring provides. For more information, visit the company’s website at assureIOM.com.
This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that Assure anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, comments with respect to strategies, expectations, planned operations and future actions of the Company. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results "may", "could", "would", "might" or "will" (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. Forward-looking information is based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of Assure to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors may be based on information currently available to Assure, including information obtained from third-party industry analysts and other third-party sources, and are based on management's current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The securities of the Corporation have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Matthew Willer, President
Cody Slach, Managing Director
Liolios Investor Relations
Released March 7, 2018